Abstract
The response of platelets to changes in the immediate environment is always a balance between activatory and inhibitory signals, the cumulative effect of which is either activation or quiescence. This is true of platelets in free flowing blood and of their regulation of haemostasis and thrombosis. In this review, we consider the endogenous inhibitory mechanisms that combine to regulate platelet activation. These include those derived from the endothelium (nitric oxide, prostacyclin, CD39), inhibitory receptors on the surface of platelets (platelet endothelial cell adhesion molecule-1, carcinoembryonic antigen cell adhesion molecule 1, G6b-B – including evidence for the role of Ig-ITIM superfamily members in the negative regulation of ITAM-associated GPVI platelet–collagen interactions and GPCR-mediated signalling and in positive regulation of “outside-in” integrin αIIbβ3-mediated signalling), intracellular inhibitory receptors (retinoic X receptor, glucocorticoid receptor, peroxisome proliferator-activated receptors, liver X receptor), and emerging inhibitory pathways (canonical Wnt signalling, Semaphorin 3A, endothelial cell specific adhesion molecule, and junctional adhesion molecule-A).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Furchgott, R. F., and Zawadzki, J. V. (1980) The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine, Nature 288, 373–376.
Bellamy, T. C., and Garthwaite, J. (2002) The receptor-like properties of nitric oxide-activated soluble guanylyl cyclase in intact cells, Mol Cell Biochem 230, 165–176.
Munzel, T., Feil, R., Mulsch, A., Lohmann, S. M., Hofmann, F., and Walter, U. (2003) Physiology and pathophysiology of vascular signaling controlled by guanosine 3′,5′-cyclic monophosphate-dependent protein kinase, Circulation 108, 2172–2183.
Eigenthaler, M., Ullrich, H., Geiger, J., Horstrup, K., Honig-Liedl, P., Wiebecke, D., and Walter, U. (1993) Defective nitrovasodilator-stimulated protein phosphorylation and calcium regulation in cGMP-dependent protein kinase-deficient human platelets of chronic myelocytic leukemia, J Biol Chem 268, 13526–13531.
Tsudo, M., Kozak, R. W., Goldman, C. K., and Waldmann, T. A. (1987) Contribution of a p75 interleukin 2 binding peptide to a high-affinity interleukin 2 receptor complex, Proc Natl Acad Sci USA 84, 4215–4218.
Eigenthaler, M., Nolte, C., Halbrugge, M., and Walter, U. (1992) Concentration and regulation of cyclic nucleotides, cyclic-nucleotide-dependent protein kinases and one of their major substrates in human platelets. Estimating the rate of cAMP-regulated and cGMP-regulated protein phosphorylation in intact cells, Eur J Biochem 205, 471–481.
Maurice, D. H., and Haslam, R. J. (1990) Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP, Mol Pharmacol 37, 671–681.
Nolte, C., Eigenthaler, M., Horstrup, K., Honig-Liedl, P., and Walter, U. (1994) Synergistic phosphorylation of the focal adhesion-associated vasodilator-stimulated phosphoprotein in intact human platelets in response to cGMP- and cAMP-elevating platelet inhibitors, Biochem Pharmacol 48, 1569–1575.
Jensen, B. O., Selheim, F., Doskeland, S. O., Gear, A. R., and Holmsen, H. (2004) Protein kinase A mediates inhibition of the thrombin-induced platelet shape change by nitric oxide, Blood 104, 2775–2782.
Cavallini, L., Coassin, M., Borean, A., and Alexandre, A. (1996) Prostacyclin and sodium nitroprusside inhibit the activity of the platelet inositol 1,4,5-trisphosphate receptor and promote its phosphorylation, J Biol Chem 271, 5545–5551.
Mullershausen, F., Friebe, A., Feil, R., Thompson, W. J., Hofmann, F., and Koesling, D. (2003) Direct activation of PDE5 by cGMP: long-term effects within NO/cGMP signaling, J Cell Biol 160, 719–727.
Butt, E., Abel, K., Krieger, M., Palm, D., Hoppe, V., Hoppe, J., and Walter, U. (1994) cAMP- and cGMP-dependent protein kinase phosphorylation sites of the focal adhesion vasodilator-stimulated phosphoprotein (VASP) in vitro and in intact human platelets, J Biol Chem 269, 14509–14517.
Waldmann, R., Nieberding, M., and Walter, U. (1987) Vasodilator-stimulated protein phosphorylation in platelets is mediated by cAMP- and cGMP-dependent protein kinases, Eur J Biochem 167, 441–448.
Miura, Y., Kaibuchi, K., Itoh, T., Corbin, J. D., Francis, S. H., and Takai, Y. (1992) Phosphorylation of smg p21B/rap1B p21 by cyclic GMP-dependent protein kinase, FEBS Lett 297, 171–174.
Danielewski, O., Schultess, J., and Smolenski, A. (2005) The NO/cGMP pathway inhibits Rap 1 activation in human platelets via cGMP-dependent protein kinase I, Thromb Haemost 93, 319–325.
Reid, H. M., and Kinsella, B. T. (2003) The alpha, but not the beta, isoform of the human thromboxane A2 receptor is a target for nitric oxide-mediated desensitization. Independent modulation of Tp alpha signaling by nitric oxide and prostacyclin, J Biol Chem 278, 51190–51202.
Sase, K., and Michel, T. (1995) Expression of constitutive endothelial nitric oxide synthase in human blood platelets., Life Sciences, 2049–2055.
Mehta, J. L., Chen, L. Y., Kone, B. C., Mehta, P., and Turner, P. (1995) Identification of constitutive and inducible forms of nitric oxide synthase in human platelets., J Lab Clin Med 125, 370–377.
Freedman, J. E., Loscalzo, J., Barnard, M. R., Alpert, C., Keaney, J. F., and Michelson, A. D. (1997) Nitric oxide released from activated platelets inhibits platelet recruitment, J Clin Invest 100, 350–356.
Malinski, T., Radomski, M. W., Taha, Z., and Moncada, S. (1993) Direct electrochemical measurement of nitric oxide released from human platelets, Biochem Biophys Res Commun 194, 960–965.
Lantoine, F., Brunet, A., Bedioui, F., Devynck, J., and Devynck, M. A. (1995) Direct measurement of nitric oxide production in platelets: relationship with cytosolic Ca2+ concentration, Biochem Biophys Res Commun 215, 842–848.
Riba, R., Sharifi, M., Farndale, R. W., and Naseem, K. M. (2005) Regulation of platelet guanylyl cyclase by collagen: evidence that Glycoprotein VI mediates platelet nitric oxide synthesis in response to collagen, Thromb Haemost 94, 395–403.
Stojanovic, A., Marjanovic, J. A., Brovkovych, V. M., Peng, X., Hay, N., Skidgel, R. A., and Du, X. (2006) A phosphoinositide 3-kinase-AKT-nitric oxide-cGMP signaling pathway in stimulating platelet secretion and aggregation, J Biol Chem 281, 16333–16339.
Riba, R., Oberprieler, N. G., Roberts, W., and Naseem, K. M. (2006) Von Willebrand factor activates endothelial nitric oxide synthase in blood platelets by a glycoprotein Ib-dependent mechanism, J Thromb Haemost 4, 2636–2644.
Morrell, C. N., Matsushita, K., Chiles, K., Scharpf, R. B., Yamakuchi, M., Mason, R. J., Bergmeier, W., Mankowski, J. L., Baldwin, W. M., 3 rd, Faraday, N., and Lowenstein, C. J. (2005) Regulation of platelet granule exocytosis by S-nitrosylation, Proc Natl Acad Sci USA 102, 3782–3787.
Radomski, M. W., Palmer, R. M., and Moncada, S. (1990) An L-arginine/nitric oxide pathway present in human platelets regulates aggregation, Proc Natl Acad Sci USA 87, 5193–5197.
Radomski, M. W., Palmer, R. M., and Moncada, S. (1990) Characterization of the L-arginine:nitric oxide pathway in human platelets, Br J Pharmacol 101, 325–328.
Storey, R. F., and Heptinstall, S. (1999) Laboratory investigation of platelet function, Clin Lab Haematol 21, 317–329.
Williams, R. H., and Nollert, M. U. (2004) Platelet-derived NO slows thrombus growth on a collagen type III surface, Thromb J 2, 11.
Li, W., Mital, S., Ojaimi, C., Csiszar, A., Kaley, G., and Hintze, T. H. (2004) Premature death and age-related cardiac dysfunction in male eNOS-knockout mice, J Mol Cell Cardiol 37, 671–680.
Iafrati, M. D., Vitseva, O., Tanriverdi, K., Blair, P., Rex, S., Chakrabarti, S., Varghese, S., and Freedman, J. E. (2005) Compensatory mechanisms influence hemostasis in setting of eNOS deficiency, Am J Physiol Heart Circ Physiol 288, H1627-1632.
Freedman, J. E., Sauter, R., Battinelli, E. M., Ault, K., Knowles, C., Huang, P. L., and Loscalzo, J. (1999) Deficient platelet-derived nitric oxide and enhanced hemostasis in mice lacking the NOSIII gene, Circ Res 84, 1416–1421.
Gambaryan, S., Kobsar, A., Hartmann, S., Birschmann, I., Kuhlencordt, P. J., Muller-Esterl, W., Lohmann, S. M., and Walter, U. (2008) NO-synthase-/NO-independent regulation of human and murine platelet soluble guanylyl cyclase activity, J Thromb Haemost 6, 1376–1384.
Naseem, K. M., and Riba, R. (2008) Unresolved roles of platelet nitric oxide synthase, J Thromb Haemost 6, 10–19.
Naseem, K. M. (2008) eNOS, iNOS or no NOS, that is the question!, J Thromb Haemost 6, 1373–1375.
Marcondes, S., Cardoso, M. H., Morganti, R. P., Thomazzi, S. M., Lilla, S., Murad, F., De Nucci, G., and Antunes, E. (2006) Cyclic GMP-independent mechanisms contribute to the inhibition of platelet adhesion by nitric oxide donor: a role for alpha-actinin nitration, Proc Natl Acad Sci USA 103, 3434–3439.
Oberprieler, N. G., Roberts, W., Riba, R., Graham, A. M., Homer-Vanniasinkam, S., and Naseem, K. M. (2007) cGMP-independent inhibition of integrin alphaIIbbeta3-mediated platelet adhesion and outside-in signalling by nitric oxide, FEBS Lett 581, 1529–1534.
Shah, C. M., Bell, S. E., Locke, I. C., Chowdrey, H. S., and Gordge, M. P. (2007) Interactions between cell surface protein disulphide isomerase and S-nitrosoglutathione during nitric oxide delivery, Nitric Oxide 16, 135–142.
Gordge, M. P., Hothersall, J. S., and Noronha-Dutra, A. A. (1998) Evidence for a cyclic GMP-independent mechanism in the anti-platelet action of S-nitrosoglutathione, Br J Pharmacol 124, 141–148.
Crane, M. S., Rossi, A. G., and Megson, I. L. (2005) A potential role for extracellular nitric oxide generation in cGMP-independent inhibition of human platelet aggregation: biochemical and pharmacological considerations, Br J Pharmacol 144, 849–859.
Tsikas, D., Ikic, M., Tewes, K. S., Raida, M., and Frolich, J. C. (1999) Inhibition of platelet aggregation by S-nitroso-cysteine via cGMP-independent mechanisms: evidence of inhibition of thromboxane A2 synthesis in human blood platelets, FEBS Lett 442, 162–166.
Dangel, O., Mergia, E., Karlisch, K., Groneberg, D., Koesling, D., and Friebe, A. (2010) Nitric oxide-sensitive guanylyl cyclase is the only nitric oxide receptor mediating platelet inhibition, J Thromb Haemost 8, 1343–1352.
Radomski, M. W., Palmer, R. M., and Moncada, S. (1987) The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium, Biochem Biophys Res Commun 148, 1482–1489.
Radomski, M. W., Palmer, R. M., and Moncada, S. (1987) The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide, Br J Pharmacol 92, 639–646.
Lidbury, P. S., Antunes, E., de Nucci, G., and Vane, J. R. (1989) Interactions of iloprost and sodium nitroprusside on vascular smooth muscle and platelet aggregation, Br J Pharmacol 98, 1275–1280.
Weksler, B. B., Marcus, A. J., and Jaffe, E. A. (1977) Synthesis of prostaglandin I2 (prostacyclin) by cultured human and bovine endothelial cells, Proc Natl Acad Sci USA 74, 3922–3926.
Ingerman-Wojenski, C., Silver, M. J., Smith, J. B., and Macarak, E. (1981) Bovine endothelial cells in culture produce thromboxane as well as prostacyclin, J Clin Invest 67, 1292–1296.
Moncada, S., Gryglewski, R., Bunting, S., and Vane, J. R. (1976) An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation, Nature 263, 663–665.
Gryglewski, R. J., Bunting, S., Moncada, S., Flower, R. J., and Vane, J. R. (1976) Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides, Prostaglandins 12, 685–713.
Needleman, P., Turk, J., Jakschik, B. A., Morrison, A. R., and Lefkowith, J. B. (1986) Arachidonic acid metabolism, Annu Rev Biochem 55, 69–102.
Hamberg, M., Svensson, J., and Samuelsson, B. (1975) Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides, Proc Natl Acad Sci USA 72, 2994–2998.
FitzGerald, G. A. (1991) Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists, Am J Cardiol 68, 11B-15B.
Marnett, L. J., Rowlinson, S. W., Goodwin, D. C., Kalgutkar, A. S., and Lanzo, C. A. (1999) Arachidonic acid oxygenation by COX-1 and COX-2. Mechanisms of catalysis and inhibition, J Biol Chem 274, 22903–22906.
Smith, W. L., DeWitt, D. L., and Garavito, R. M. (2000) Cyclooxygenases: structural, cellular, and molecular biology, Annu Rev Biochem 69, 145–182.
Patrignani, P., Sciulli, M. G., Manarini, S., Santini, G., Cerletti, C., and Evangelista, V. (1999) COX-2 is not involved in thromboxane biosynthesis by activated human platelets, J Physiol Pharmacol 50, 661–667.
Spisni, E., Bartolini, G., Orlandi, M., Belletti, B., Santi, S., and Tomasi, V. (1995) Prostacyclin (PGI2) synthase is a constitutively expressed enzyme in human endothelial cells, Exp Cell Res 219, 507–513.
Smith, W. L., DeWitt, D. L., and Allen, M. L. (1983) Bimodal distribution of the prostaglandin I2 synthase antigen in smooth muscle cells, J Biol Chem 258, 5922–5926.
Needleman, P., Moncada, S., Bunting, S., Vane, J. R., Hamberg, M., and Samuelsson, B. (1976) Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxides, Nature 261, 558–560.
Hsu, P. Y., Tsai, A. L., Kulmacz, R. J., and Wang, L. H. (1999) Expression, purification, and spectroscopic characterization of human thromboxane synthase, J Biol Chem 274, 762–769.
Dutta-Roy, A. K., and Sinha, A. K. (1987) Purification and properties of prostaglandin E1/prostacyclin receptor of human blood platelets, J Biol Chem 262, 12685–12691.
Tsai, A. L., Hsu, M. J., Vijjeswarapu, H., and Wu, K. K. (1989) Solubilization of prostacyclin membrane receptors from human platelets, J Biol Chem 264, 61–67.
Jones, R. L., Qian, Y., Wong, H. N., Chan, H., and Yim, A. P. (1997) Prostanoid action on the human pulmonary vascular system, Clin Exp Pharmacol Physiol 24, 969–972.
Tateson, J. E., Moncada, S., and Vane, J. R. (1977) Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets, Prostaglandins 13, 389–397.
Gorman, R. R., Bunting, S., and Miller, O. V. (1977) Modulation of human platelet adenylate cyclase by prostacyclin (PGX), Prostaglandins 13, 377–388.
Kobayashi, T., Ushikubi, F., and Narumiya, S. (2000) Amino acid residues conferring ligand binding properties of prostaglandin I and prostaglandin D receptors. Identification by site-directed mutagenesis, J Biol Chem 275, 24294–24303.
Siess, W. (1989) Molecular mechanisms of platelet activation, Physiol Rev 69, 58–178.
Armstrong, R. A. (1996) Platelet prostanoid receptors, Pharmacol Ther 72, 171–191.
Robson, S. C., Sevigny, J., and Zimmermann, H. (2006) The E-NTPDase family of ectonucleotidases: Structure function relationships and pathophysiological significance, Purinergic Signal 2, 409–430.
Kansas, G. S., Wood, G. S., and Tedder, T. F. (1991) Expression, distribution, and biochemistry of human CD39. Role in activation-associated homotypic adhesion of lymphocytes, J Immunol 146, 2235–2244.
Marcus, A. J., Broekman, M. J., Drosopoulos, J. H., Islam, N., Alyonycheva, T. N., Safier, L. B., Hajjar, K. A., Posnett, D. N., Schoenborn, M. A., Schooley, K. A., Gayle, R. B., and Maliszewski, C. R. (1997) The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39, J Clin Invest 99, 1351–1360.
Koziak, K., Sevigny, J., Robson, S. C., Siegel, J. B., and Kaczmarek, E. (1999) Analysis of CD39/ATP diphosphohydrolase (ATPDase) expression in endothelial cells, platelets and leukocytes, Thromb Haemost 82, 1538–1544.
Plesner, L. (1995) Ecto-ATPases: identities and functions, Int Rev Cytol 158, 141–214.
Marcus, A. J., Safier, L. B., Hajjar, K. A., Ullman, H. L., Islam, N., Broekman, M. J., and Eiroa, A. M. (1991) Inhibition of platelet function by an aspirin-insensitive endothelial cell ADPase. Thromboregulation by endothelial cells, J Clin Invest 88, 1690–1696.
Zimmermann, H. (1992) 5′-Nucleotidase: molecular structure and functional aspects, Biochem J 285 ( Pt 2), 345–365.
Dwyer, K. M., Robson, S. C., Nandurkar, H. H., Campbell, D. J., Gock, H., Murray-Segal, L. J., Fisicaro, N., Mysore, T. B., Kaczmarek, E., Cowan, P. J., and d’Apice, A. J. (2004) Thromboregulatory manifestations in human CD39 transgenic mice and the implications for thrombotic disease and transplantation, J Clin Invest 113, 1440–1446.
Marcus, A. J., Broekman, M. J., Drosopoulos, J. H., Islam, N., Pinsky, D. J., Sesti, C., and Levi, R. (2003) Heterologous cell-cell interactions: thromboregulation, cerebroprotection and cardioprotection by CD39 (NTPDase-1), J Thromb Haemost 1, 2497–2509.
Burnstock, G. (2002) Purinergic signaling and vascular cell proliferation and death, Arterioscler Thromb Vasc Biol 22, 364–373.
Jackson, D. E., Ward, C. M., Wang, R., and Newman, P. J. (1997) The protein-tyrosine phosphatase SHP-2 binds platelet/endothelial cell adhesion molecule-1 (PECAM-1) and forms a distinct signaling complex during platelet aggregation, J. Biol. Chem. 272, 6986–6993.
Newman, P. J. (1999) Switched at birth: a new family for PECAM-1, J Clin Invest 103, 5–9.
Gibbins, J. M. (2002) The negative regulation of platelet function: extending the role of the ITIM, Trends Cardiovasc Med 12, 213–219.
Wong, C., Liu, Y., Yip, J., Chand, R., Wee, J. L., Oates, L., Nieswandt, B., Reheman, A., Ni, H., Beauchemin, N., and Jackson, D. E. (2009) CEACAM1 negatively regulates platelet-collagen interactions and thrombus growth in vitro and in vivo, Blood 113, 1818–1828.
Newland, S. A., Macaulay, I. C., Floto, R. A., de Vet, E. C., Ouwehand, W. H., Watkins, N. A., Lyons, P. A., and Campbell, R. D. (2007) The novel inhibitory receptor G6B is expressed on the surface of platelets and attenuates platelet function in vitro, Blood 109, 4806–4809.
Senis, Y. A., Tomlinson, M. G., Garcia, A., Dumon, S., Heath, V. L., Herbert, J., Cobbold, S. P., Spalton, J. C., Ayman, S., Antrobus, R., Zitzmann, N., Bicknell, R., Frampton, J., Authi, K. S., Martin, A., and Wakelam, M. J. O. (2007) A comprehensive proteomics and genomics analysis reveals novel transmembrane proteins in human platelets and mouse megakaryocytes including G6b-B, a novel immunoreceptor tyrosine-based inhibitory motif protein, Molecular & Cellular Proteomics 6, 548–564.
Mori, J., Pearce, A. C., Spalton, J. C., Grygielska, B., Eble, J. A., Tomlinson, M. G., Senis, Y. A., and Watson, S. P. (2008) G6b-B Inhibits Constitutive and Agonist-induced Signaling by Glycoprotein VI and CLEC-2, Journal of Biological Chemistry 283, 35419–35427.
Macaulay, I. C., Tijssen, M. R., Thijssen-Timmer, D. C., Gusnanto, A., Steward, M., Burns, P., Langford, C. F., Ellis, P. D., Dudbridge, F., Zwaginga, J. J., Watkins, N. A., van der Schoot, C. E., and Ouwehand, W. H. (2007) Comparative gene expression profiling of in vitro differentiated megakaryocytes and erythroblasts identifies novel activatory and inhibitory platelet membrane proteins, Blood 109, 3260–3269.
Newman, P. J., Berndt, M. J., Gorski, J., White, G. C., Lyman, S., Paddock, C., and Muller, W. A. (1990) PECAM-1 (CD31) cloning and relation to adhesion molecules of the immunoglobulin gene superfamily., Science 247, 1219–1222.
Kirschbaum, N. E., Gumina, R. J., and Newman, P. J. (1994) Organization of the gene for human platelet/endothelial cell adhesion molecule-1 shows alternatively spliced isoforms and a functionally complex cytoplasmic domain, Blood 84, 4028–4037.
Ohto, H., Maeda, H., Shibata, Y., Chen, R. F., Ozaki, Y., Higashihara, M., Takeuchi, A., and Tohyama, H. (1985) A novel leukocyte differentiation antigen: two monoclonal antibodies TM2 and TM3 define a 120-kd molecule present on neutrophils, monocytes, platelets, and activated lymphoblasts, Blood 66, 873–881.
Goyert, S. M., Ferrero, E. M., Seremetis, S. V., Winchester, R. J., Silver, J., and Mattison, A. C. (1986) Biochemistry and expression of myelomonocytic antigens, J Immunol 137, 3909–3914.
Lyons, A. B., Cooper, S. J., Cole, S. R., and Ashman, L. K. (1988) Human myeloid differentiation antigens identified by monoclonal antibodies to the myelomonocytic leukemia cell line RC-2A, Pathology 20, 137–146.
Cabanas, C., Sanchez-Madrid, F., Bellon, T., Figdor, C. G., Te Velde, A. A., Fernandez, J. M., Acevedo, A., and Bernabeu, C. (1989) Characterization of a novel myeloid antigen regulated during differentiation of monocytic cells, Eur J Immunol 19, 1373–1378.
Newman, P. J. (1994) The role of PECAM-1 in vascular cell biology, Ann N Y Acad Sci 714, 165–174.
Wu, X. W., and Lian, E. C. (1997) Binding properties and inhibition of platelet aggregation by a monoclonal antibody to CD31 (PECAM-1), Arterioscler Thromb Vasc Biol 17, 3154–3158.
Metzelaar, M. J., Korteweg, J., Sixma, J. J., and Nieuwenhuis, H. K. (1991) Biochemical characterization of PECAM-1 (CD31 antigen) on human platelets, Thromb Haemost 66, 700–707.
Mazurov, A. V., Vinogradov, D. V., Kabaeva, N. V., Antonova, G. N., Romanov, Y. A., Vlasik, T. N., Antonov, A. S., and Smirnov, V. N. (1991) A monoclonal antibody, VM64, reacts with a 130 kDa glycoprotein common to platelets and endothelial cells: heterogeneity in antibody binding to human aortic endothelial cells, Thromb Haemost 66, 494–499.
Cicmil, M., Thomas, J. M., Sage, T., Barry, F. A., Leduc, M., Bon, C., and Gibbins, J. M. (2000) Collagen, Convulxin, and Thrombin Stimulate Aggregation-independent Tyrosine Phosphorylation of CD31 in Platelets. Evidence for the involvement of Src family kinases., J. Biol. Chem. 275, 27339–27347.
Buckley, C. D., Doyonnas, R., Newton, J. P., Blystone, S. D., Brown, E. J., Watt, S. M., and Simmons, D. L. (1996) Identification of avb3 as a heterotypic ligand for CD31/PECAM-1., J.Cell Sci. 109, 437–445.
Patil, S., Newman, D. K., and Newman, P. J. (2001) Platelet endothelial cell adhesion molecule-1 serves as an inhibitory receptor that modulates platelet responses to collagen, Blood 97, 1727–1732.
Cramer, E. M., Berger, G., and Berndt, M. C. (1994) Platelet alpha-granule and plasma membrane share two new components: CD9 and PECAM-1, Blood 84, 1722–1730.
Jackson, D. E., Kupcho, K. R., and Newman, P. J. (1997) Characterization of Phosphotyrosine Binding Motifs in the Cytoplasmic Domain of Platelet/Endothelial Cell Adhesion Molecule-1 (PECAM-1) that are required for the Cellular Association and Activation of the Protein-tyrosine Phosphatase, SHP-2, J. Biol. Chem. 272, 24868–24875.
Vivier, E., and Daeron, M. (1997) Immunoreceptor tyrosine-based inhibitory motifs., Immunol. Today 18, 286–291.
Rathore, V., Stapleton, M. A., Hillery, C. A., Montgomery, R. R., Nichols, T. C., Merricks, E. P., Newman, D. K., and Newman, P. J. (2003) PECAM-1 negatively regulates GPIb/V/IX signaling in murine platelets, Blood 102, 3658–3664.
Jones, K. L., Hughan, S. C., Dopheide, S. M., Farndale, R. W., Jackson, S. P., and Jackson, D. E. (2001) Platelet endothelial cell adhesion molecule-1 is a negative regulator of platelet-collagen interactions, Blood 98, 1456–1463.
Cao, M. Y., Huber, M., Beauchemin, N., Famiglietti, J., Albelda, S. M., and Veillette, A. (1998) Regulation of mouse PECAM-1 tyrosine phosphorylation by the Src and Csk families of protein-tyrosine kinases, J Biol Chem 273, 15765–15772.
Chiu, Y. J., McBeath, E., and Fujiwara, K. (2008) Mechanotransduction in an extracted cell model: Fyn drives stretch- and flow-elicited PECAM-1 phosphorylation, J Cell Biol 182, 753–763.
Newman, D. K., Hamilton, C., and Newman, P. J. (2001) Inhibition of antigen-receptor signaling by Platelet Endothelial Cell Adhesion Molecule-1 (CD31) requires functional ITIMs, SHP-2, and p56(lck), Blood 97, 2351–2357.
Hua, C. T., Gamble, J. R., Vadas, M. A., and Jackson, D. E. (1998) Recruitment and Activation of SHP-1 Protein-tyrosine Phosphatase by Human Platelet Endothelial Cell Adhesion Molecule-1 (PECAM-1). Identification of Immunoreceptor Tyrosine-Based Inhibitory Motif-Like Binding Motifs and Substrates, J. Biol. Chem. 273, 28332–28340.
Pumphrey, N. J., Taylor, V. T., Freeman, S., Douglas, M. R., Bradfield, P. F., Young, S. P., Lord, J. M., Wakelam, M. J. O., Bird, I. N., Salmon, M., and Buckley, C. D. (1999) Differetial association of cytoplasmic signalling molecules SHP-1, SHP-2, SHIP and phosphlipase C-γ1 with PECAM-1/CD31, FEBS Lett. 450, 77–83.
Relou, I. A. M., Gorter, G., Ferreira, I. A., van Rijn, H. J. M., and Akkerman, J. W. N. (2003) Platelet endothelial cell adhesion molecule-1 (PECAM-1) inhibits low density lipoprotein-induced signaling in platelets, Journal of Biological Chemistry 278, 32638–32644.
Thai le, M., Ashman, L. K., Harbour, S. N., Hogarth, P. M., and Jackson, D. E. (2003) Physical proximity and functional interplay of PECAM-1 with the Fc receptor Fc gamma RIIa on the platelet plasma membrane, Blood 102, 3637–3645.
Moraes, L. A., Barrett, N. E., Jones, C. I., Holbrook, L. M., Spyridon, M., Sage, T., Newman, D. K., and Gibbins, J. M. (2010) PECAM-1 regulates collagen-stimulated platelet function by modulating the association of PI3 Kinase with Gab1 and LAT, J Thromb Haemost.
Sardjono, C. T., Harbour, S. N., Yip, J. C., Paddock, C., Tridandapani, S., Newman, P. J., and Jackson, D. E. (2006) Palmitoylation at Cys(595) is essential for PECAM-I localisation into membrane microdomains and for efficient PECAM-I-mediated cytoprotection, Thrombosis and Haemostasis 96, 756–766.
Cicmil, M., Thomas, J. M., Leduc, M., Bon, C., and Gibbins, J. M. (2002) PECAM-1 signalling inhibits the activation of human platelets, Blood 99, 137–144.
Jones, C. I., Garner, S. F., Moraes, L. A., Kaiser, W. J., Rankin, A., Ouwehand, W. H., Goodall, A. H., and Gibbins, J. M. (2009) PECAM-1 expression and activity negatively regulate multiple platelet signaling pathways, FEBS Lett 583, 3618–3624.
Falati, S., Patil S., Gross, P. L., Stapleton, M., Merrill-Skoloff G., Barrett, N. E., Pixton, K. L., Weiler H., Cooley B., Newman D.K., Newman, P. J., Furie, B. C., Furie B., and Gibbins, J. M. (2006) Platelet PECAM-1 inhibits thrombus formation in vivo, Blood 107, 535–541.
Novinska, M. S., Rathoare, V., Newman, D. K., and Newman, P. J. (2007) PECAM-1, Platelets, Chapter 11, pages 221–230.
Gibbins, J., Asselin, J., Farndale, R., Barnes, M., Law, C. L., and Watson, S. P. (1996) Tyrosine phosphorylation of the Fc receptor gamma-chain in collagen-stimulated platelets, J Biol Chem 271, 18095–18099.
Gibbins, J. M., Okuma, M., Farndale, R., Barnes, M., and Watson, S. P. (1997) Glycoprotein VI is the collagen receptor in platelets which underlies tyrosine phosphorylation of the Fc receptor γ-chain, FEBS Letters 413, 255–259.
Poole, A., Gibbins, J. M., Turner, M., vanVugt, M. J., vandeWinkel, J. G. J., Saito, T., Tybulewicz, V. L. J., and Watson, S. P. (1997) The Fc receptor gamma-chain and the tyrosine kinase Syk are essential for activation of mouse platelets by collagen, 16, 2333–2341.
Falati, S., Edmead, C. E., and Poole, A. W. (1999) Glycoprotein Ib-V-IX, a receptor for von Willebrand factor, couples physically and functionally to the Fc receptor gamma- chain, Fyn, and Lyn to activate human platelets, Blood 94, 1648–1656.
Reth, M. (1989) Antigen receptor tail clue, Nature 338, 383–384.
Odin, J. A., Edberg, J. C., Painter, C. J., Kimberly, R. P., and Unkeless, J. C. (1991) Regulation of phagocytosis and [Ca2+]i flux by distinct regions of an Fc receptor, Science 254, 1785–1788.
Dhanjal, T. S., Ross, E. A., Auger, J. M., McCarty, O. J., Hughes, C. E., Senis, Y. A., Buckley, C. D., and Watson, S. P. (2007) Minimal regulation of platelet activity by PECAM-1, Platelets 18, 56–67.
Wee, J. L., and Jackson, D. E. (2005) The Ig-ITIM superfamily member PECAM-1 regulates the “outside-in” signaling properties of integrin alpha(IIb)beta(3) in platelets, Blood 106, 3816–3823.
Berman, M. E., and Muller, W. A. (1995) Ligation of Platelet Endothelial-Cell Adhesion Molecule-1 (Pecam-1/Cd31) on Monocytes and Neutrophils Increases Binding- Capacity of Leukocyte Cr3 (Cd11b/Cd18), J. Immunol. 154, 299–307.
Berman, M. E., Xie, Y., and Muller, W. A. (1996) Roles of platelet endothelial cell adhesion molecule-1 (PECAM- 1,CD31) in natural killer cell transendothelial migration and beta(2) integrin activation, J. Immunol. 156, 1515–1524.
Chiba, R., Nakagawa, N., Kuroasawa, K., Tanaka, Y., Saito, Y., and Iwamoto, I. (1999) Ligation of CD31(PECAM-1) on endothelial cells increases adhesive function of αvβ3 integrin and enhances b1 integrin mediated adhesion of eosinophilis to endothelial cells, Blood 94, 1319–1329.
Pellegatta, F., Chierchia, S. L., and Zocchi, M. R. (1998) Functional association of platelet endothelial cell adhesion molecule-1 and phosphoinositide 3-kinase in human neutrophils, Journal of Biological Chemistry 273, 27768–27771.
Piali, L., Albelda, S. M., Baldwin, H. S., Hammel, P., Gisler, R. H., and Imhof, B. A. (1993) Murine platelet endothelial cell adhesion molecule (PECAM-1/CD31) modulates b2 integrins on lymphokine-activated killer cells., Eur.J.Immunol. 23, 2464–2471.
Tanaka, Y., Albelda, S. M., Horgan, K. J., van Seventer, G. A., Shimizu, Y., Newman, W., Hallam, J., Newman, P. J., Buck, C. A., and Shaw, S. (1992) CD31 expressed on distinctive T cell subsets is a preferential amplifier of b1 integrin-mediated adhesion, J Exp Med 176, 245–253.
Zhao, T. M., and Newman, P. J. (2001) Integrin activation by regulated dimerization and oligomerization of platelet endothelial cell adhesion molecule (PECAM)-1 from within the cell, Journal of Cell Biology 152, 65–73.
Leavesley, D. I., Oliver, J. M., Swart, B. W., Berndt, M. C., Haylock, D. N., and Simmons, P. J. (1994) Signals from Platelet Endothelial-Cell Adhesion Molecule Enhance the Adhesive Activity of the Very Late Antigen-4 Integrin of Human Cd34(+) Hematopoietic Progenitor Cells, J. Immunol. 153, 4673–4683.
Varon, D., Jackson, D. E., Shenkman, B., Dardik, R., Tamarin, I., Savion, N., and Newman, P. J. (1998) Platelet/endothelial cell adhesion molecule-1 serves as a costimulatory agonist receptor that modulates integrin-dependent adhesion and aggregation of human platelets, Blood 91, 500–507.
Reedquist, K. A., Ross, E., Koop, E. A., Wolthuis, R. M. F., Zwartkruis, F. J. T., van Kooyk, Y., Salmon, M., Buckley, C. D., and Bos, J. L. (2000) The small GTPase, Rap1, mediates CD31-induced integrin adhesion, Journal of Cell Biology 148, 1151–1158.
Wilkinson, R., Lyons, A. B., Roberts, D., Wong, M. X., Bartley, P. A., and Jackson, D. E. (2002) Platelet endothelial cell adhesion molecule-1 (PECAM-1/CD31) acts as a regulator of B-cell development, B-cell antigen receptor (BCR)-mediated activation, and autoimmune disease, Blood 100, 184–193.
Gao, C., Sun, W., Christofidou-Solomidou, M., Sawada, M., Newman, D. K., Bergom, C., Albelda, S. M., Matsuyama, S., and Newman, P. J. (2003) PECAM-1 functions as a specific and potent inhibitor of mitochondrial-dependent apoptosis, Blood 102, 169–179.
Wong, M. X., Roberts, D., Bartley, P. A., and Jackson, D. E. (2002) Absence of platelet endothelial cell adhesion molecule-1 (CD31) leads to increased severity of local and systemic IgE-mediated anaphylaxis and modulation of mast cell activation, J Immunol 168, 6455–6462.
Graesser, D., Solowiej, A., Bruckner, M., Osterweil, E., Juedes, A., Davis, S., Ruddle, N. H., Engelhardt, B., and Madri, J. A. (2002) Altered vascular permeability and early onset of experimental autoimmune encephalomyelitis in PECAM-1-deficient mice, J Clin Invest 109, 383–392.
Albelda, S. M., Muller, W. A., Buck, C. A., and Newman, P. J. (1991) Molecular and cellular properties of PECAM-1 (endoCAM/CD31): a novel vascular cell-cell adhesion molecule, J Cell Biol 114, 1059–1068.
Albelda, S. M., Oliver, P. D., Romer, L. H., and Buck, C. A. (1990) EndoCAM: a novel endothelial cell-cell adhesion molecule, J Cell Biol 110, 1227–1237.
Schimmenti, L. A., Yan, H. C., Madri, J. A., and Albelda, S. M. (1992) Platelet endothelial cell adhesion molecule, PECAM-1, modulates cell migration, J Cell Physiol 153, 417–428.
Muller, W. A., Weigl, S. A., Deng, X., and Phillips, D. M. (1993) PECAM-1 is required for transendothelial migration of leukocytes, J Exp Med 178, 449–460.
DeLisser, H. M., Christofidou-Solomidou, M., Strieter, R. M., Burdick, M. D., Robinson, C. S., Wexler, R. S., Kerr, J. S., Garlanda, C., Merwin, J. R., Madri, J. A., and Albelda, S. M. (1997) Involvement of endothelial PECAM-1/CD31 in angiogenesis, Am J Pathol 151, 671–677.
Chimini, G. (2002) Apoptosis: repulsive encounters, Nature 418, 139–141.
Ferrero, E., Ferrero, M. E., Pardi, R., and Zocchi, M. R. (1995) The platelet endothelial cell adhesion molecule-1 (PECAM1) contributes to endothelial barrier function, FEBS Lett 374, 323–326.
Gratzinger, D., Barreuther, M., and Madri, J. A. (2003) Platelet-endothelial cell adhesion molecule-1 modulates endothelial migration through its immunoreceptor tyrosine-based inhibitory motif, Biochem Biophys Res Commun 301, 243–249.
O’Brien, C. D., Cao, G., Makrigiannakis, A., and DeLisser, H. M. (2004) Role of immunoreceptor tyrosine-based inhibitory motifs of PECAM-1 in PECAM-1-dependent cell migration, Am J Physiol Cell Physiol 287, C1103-1113.
Zhu, J. X., Cao, G., Williams, J. T., and Delisser, H. M. (2010) SHP-2 phosphatase activity is required for PECAM-1-dependent cell motility, Am J Physiol Cell Physiol 299, C854-865.
Hansson, M., Odin, P., Johansson, S., and Obrink, B. (1990) Comparison and functional characterization of C-CAM, glycoprotein IIb/IIIa and integrin beta 1 in rat platelets, Thromb Res 58, 61–73.
de Vet, E., Aguado, B., and Campbell, R. D. (2001) G6b, a novel immunoglobulin superfamily member encoded in the human major histocompatibility complex, interacts with SHP-1 and SHP-2, Journal of Biological Chemistry 276, 42070–42076.
Ali, F. Y., Davidson, S. J., Moraes, L. A., Traves, S. L., Paul-Clark, M., Bishop-Bailey, D., Warner, T. D., and Mitchell, J. A. (2006) Role of nuclear receptor signaling in platelets: antithrombotic effects of PPARbeta, Faseb J 20, 326–328.
Moraes, L. A., Paul-Clark, M. J., Rickman, A., Flower, R. J., Goulding, N. J., and Perretti, M. (2005) Ligand-specific glucocorticoid receptor activation in human platelets, Blood 106, 4167–4175.
Moraes, L. A., Swales, K. E., Wray, J. A., Damazo, A., Gibbins, J. M., Warner, T. D., and Bishop-Bailey, D. (2007) Nongenomic signaling of the retinoid X receptor through binding and inhibiting Gq in human platelets, Blood 109, 3741–3744.
Spyridon M, Moraes, L. A., Jones, C. I., Sage, T., Sasikumar, P., Bucci, G., and Gibbins, J. M. (2010) LXR as a novel anti-thrombotic target, Under revision.
Akbiyik, F., Ray, D. M., Gettings, K. F., Blumberg, N., Francis, C. W., and Phipps, R. P. (2004) Human bone marrow megakaryocytes and platelets express PPARgamma, and PPARgamma agonists blunt platelet release of CD40 ligand and thromboxanes, Blood 104, 1361–1368.
Ali, F. Y., Davidson, S. J., Moraes, L. A., Traves, S. L., Paul-Clark, M., Bishop-Bailey, D., Warner, T. D., and Mitchell, J. A. (2005) Role of nuclear receptor signaling in platelets: antithrombotic effects of PPAR beta, Faseb Journal 19, 326- + .
Moraes, L. A., Spyridon, M., Kaiser, W. J., Jones, C. I., Sage, T., Atherton, R. E. L., and Gibbins, J. M. (2010) Non-genomic effects of PPAR gamma ligands: inhibition of GPVI-stimulated platelet activation, J Thromb Haemost 8, 577–587.
Berger, J. P., Akiyama, T. E., and Meinke, P. T. (2005) PPARs: therapeutic targets for metabolic disease, Trends in Pharmacological Sciences 26, 244–251.
Irons, B. K., Greene, R. S., Mazzolini, T. A., Edwards, K. L., and Sleeper, R. B. (2006) Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus, Pharmacotherapy 26, 168–181.
Marx, N., Duez, H., Fruchart, J. C., and Staels, B. (2004) Peroxisome proliferator-activated receptors and atherogenesis - Regulators of gene expression in vascular cells, Circulation Research 94, 1168–1178.
Moraes, L. A., Piqueras, L., and Bishop-Bailey, D. (2006) Peroxisome proliferator-activated receptors and inflammation, Pharmacol Ther 110, 371–385.
Lee, C. H., Chawla, A., Urbiztondo, N., Liao, D., Boisvert, W. A., Evans, R. M., and Curtiss, L. K. (2003) Transcriptional repression of atherogenic inflammation: modulation by PPARdelta, Science 302, 453–457.
Forman, B. M., Chen, J., and Evans, R. M. (1997) Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta, Proc Natl Acad Sci USA 94, 4312–4317.
Joseph, S. B., Castrillo, A., Laffitte, B. A., Mangelsdorf, D. J., and Tontonoz, P. (2003) Reciprocal regulation of inflammation and lipid metabolism by liver X receptors, Nature Medicine 9, 213–219.
Joseph, S. B., McKilligin, E., Pei, L. M., Watson, M. A., Collins, A. R., Laffitte, B. A., Chen, M. Y., Noh, G., Goodman, J., Hagger, G. N., Tran, J., Tippin, T. K., Wang, X. P., Lusis, A. J., Hsueh, W. A., Law, R. E., Collins, J. L., Willson, T. M., and Tontonoz, P. (2002) Synthetic LXR ligand inhibits the development of atherosclerosis in mice, Proceedings of the National Academy of Sciences of the United States of America 99, 7604–7609.
Tangirala, R. K., Bischoff, E. D., Joseph, S. B., Wagner, B. L., Walczak, R., Laffitte, B. A., Daige, C. L., Thomas, D., Heyman, R. A., Mangelsdorf, D. J., Wang, X. P., Lusis, A. J., Tontonoz, P., and Schulman, I. G. (2002) Identification of macrophage liver X receptors as inhibitors of atherosclerosis, Proceedings of the National Academy of Sciences of the United States of America 99, 11896–11901.
Goulding, N. J. (2004) The molecular complexity of glucocorticoid actions in inflammation - a four-ring circus, Curr Opin Pharmacol 4, 629–636.
Schaaf, M. J., and Cidlowski, J. A. (2002) Molecular mechanisms of glucocorticoid action and resistance, J Steroid Biochem Mol Biol 83, 37–48.
Huang, H., and He, X. (2008) Wnt/beta-catenin signaling: new (and old) players and new insights, Curr Opin Cell Biol 20, 119–125.
Logan, C. Y., and Nusse, R. (2004) The Wnt signaling pathway in development and disease, Annu Rev Cell Dev Biol 20, 781–810.
Hart, M. J., de los Santos, R., Albert, I. N., Rubinfeld, B., and Polakis, P. (1998) Downregulation of beta-catenin by human Axin and its association with the APC tumor suppressor, beta-catenin and GSK3 beta, Curr Biol 8, 573–581.
Kishida, S., Yamamoto, H., Ikeda, S., Kishida, M., Sakamoto, I., Koyama, S., and Kikuchi, A. (1998) Axin, a negative regulator of the wnt signaling pathway, directly interacts with adenomatous polyposis coli and regulates the stabilization of beta-catenin, J Biol Chem 273, 10823–10826.
Liu, C., Li, Y., Semenov, M., Han, C., Baeg, G. H., Tan, Y., Zhang, Z., Lin, X., and He, X. (2002) Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism, Cell 108, 837–847.
Yost, C., Torres, M., Miller, J. R., Huang, E., Kimelman, D., and Moon, R. T. (1996) The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3, Genes Dev 10, 1443–1454.
Aberle, H., Bauer, A., Stappert, J., Kispert, A., and Kemler, R. (1997) beta-catenin is a target for the ubiquitin-proteasome pathway, EMBO J 16, 3797–3804.
Latres, E., Chiaur, D. S., and Pagano, M. (1999) The human F box protein beta-Trcp associates with the Cul1/Skp1 complex and regulates the stability of beta-catenin, Oncogene 18, 849–854.
Liu, C., Kato, Y., Zhang, Z., Do, V. M., Yankner, B. A., and He, X. (1999) beta-Trcp couples beta-catenin phosphorylation-degradation and regulates Xenopus axis formation, Proc Natl Acad Sci USA 96, 6273–6278.
Macdonald, B. T., Semenov, M. V., and He, X. (2007) SnapShot: Wnt/beta-catenin signaling, Cell 131, 1204.
Steele, B. M., Harper, M. T., Macaulay, I. C., Morrell, C. N., Perez-Tamayo, A., Foy, M., Habas, R., Poole, A. W., Fitzgerald, D. J., and Maguire, P. B. (2009) Canonical Wnt signaling negatively regulates platelet function, Proc Natl Acad Sci USA 106, 19836–19841.
Takahashi, T., Fournier, A., Nakamura, F., Wang, L. H., Murakami, Y., Kalb, R. G., Fujisawa, H., and Strittmatter, S. M. (1999) Plexin-neuropilin-1 complexes form functional semaphorin-3A receptors, Cell 99, 59–69.
Tamagnone, L., Artigiani, S., Chen, H., He, Z., Ming, G. I., Song, H., Chedotal, A., Winberg, M. L., Goodman, C. S., Poo, M., Tessier-Lavigne, M., and Comoglio, P. M. (1999) Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates, Cell 99, 71–80.
Fournier, A. E., Nakamura, F., Kawamoto, S., Goshima, Y., Kalb, R. G., and Strittmatter, S. M. (2000) Semaphorin3A enhances endocytosis at sites of receptor-F-actin colocalization during growth cone collapse, J Cell Biol 149, 411–422.
Fan, J., Mansfield, S. G., Redmond, T., Gordon-Weeks, P. R., and Raper, J. A. (1993) The organization of F-actin and microtubules in growth cones exposed to a brain-derived collapsing factor, J Cell Biol 121, 867–878.
Serini, G., Valdembri, D., Zanivan, S., Morterra, G., Burkhardt, C., Caccavari, F., Zammataro, L., Primo, L., Tamagnone, L., Logan, M., Tessier-Lavigne, M., Taniguchi, M., Puschel, A. W., and Bussolino, F. (2003) Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function, Nature 424, 391–397.
Kashiwagi, H., Shiraga, M., Kato, H., Kamae, T., Yamamoto, N., Tadokoro, S., Kurata, Y., Tomiyama, Y., and Kanakura, Y. (2005) Negative regulation of platelet function by a secreted cell repulsive protein, semaphorin 3A, Blood 106, 913–921.
Nasdala, I., Wolburg-Buchholz, K., Wolburg, H., Kuhn, A., Ebnet, K., Brachtendorf, G., Samulowitz, U., Kuster, B., Engelhardt, B., Vestweber, D., and Butz, S. (2002) A transmembrane tight junction protein selectively expressed on endothelial cells and platelets, Journal of Biological Chemistry 277, 16294–16303.
Sobocka, M. B., Sobocki, T., Banerjee, P., Weiss, C., Rushbrook, J. I., Norin, A. J., Hartwig, J., Salifu, M. O., Markell, M. S., Babinska, A., Ehrlich, Y. H., and Kornecki, E. (2000) Cloning of the human platelet F11 receptor: a cell adhesion molecule member of the immunoglobulin superfamily involved in platelet aggregation, Blood 95, 2600–2609.
Hirata, K., Ishida, T., Penta, K., Rezaee, M., Yang, E., Wohlgemuth, J., and Quertermous, T. (2001) Cloning of an immunoglobulin family adhesion molecule selectively expressed by endothelial cells, Journal of Biological Chemistry 276, 16223–16231.
Wegmann, F., Petri, B., Khandoga, A. G., Moser, C., Khandoga, A., Volkery, S., Li, H., Nasdala, I., Brandau, O., Fassler, R., Butz, S., Krombach, F., and Vestweber, D. (2006) ESAM supports neutrophil extravasation, activation of Rho, and VEGF-induced vascular permeability, Journal of Experimental Medicine 203, 1671–1677.
Stalker, T. J., Wu, J., Morgans, A., Traxler, E. A., Wang, L., Chatterjee, M. S., Lee, D., Quertermous, T., Hall, R. A., Hammer, D. A., Diamond, S. L., and Brass, L. F. (2009) Endothelial cell specific adhesion molecule (ESAM) localizes to platelet-platelet contacts and regulates thrombus formation in vivo, Journal of Thrombosis and Haemostasis 7, 1886–1896.
Naik, M. U., Stalker, T. J., Brass, L. F., and Naik, U. P. (2008) Junctional Adhesion Molecule a Helps Maintain Integrin alpha IIb beta 3 in Resting State, Blood 112, 48–48.
Naik, M. U., Stalker, T. J., Brass, L. F., and Naik, U. P. (2009) Platelet Junctional Adhesion Molecule-A Regulates Thrombosis by Negatively Regulating Outside-in Signaling through Integrin alpha IIb beta 3, Blood 114, 69–70.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Jones, C.I., Barrett, N.E., Moraes, L.A., Gibbins, J.M., Jackson, D.E. (2012). Endogenous Inhibitory Mechanisms and the Regulation of Platelet Function. In: Gibbins, J., Mahaut-Smith, M. (eds) Platelets and Megakaryocytes. Methods in Molecular Biology, vol 788. Springer, New York, NY. https://doi.org/10.1007/978-1-61779-307-3_23
Download citation
DOI: https://doi.org/10.1007/978-1-61779-307-3_23
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-61779-306-6
Online ISBN: 978-1-61779-307-3
eBook Packages: Springer Protocols